Trial Profile
A Study Evaluating Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients with Nonvalvular Atrial Fibrillation Treated with Apixaban or Warfarin in the Real-World Setting.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Thromboembolism
- Focus Adverse reactions
- 30 Jun 2017 New trial record